NASDAQ:MCRB Seres Therapeutics Q3 2026 Earnings Report $2.72 -0.18 (-6.21%) Closing price 10/7/2026 04:00 PM EasternExtended Trading$2.88 +0.17 (+6.07%) As of 05:09 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Seres Therapeutics EPS ResultsActual EPSN/AConsensus EPS -$1.01Beat/MissN/AOne Year Ago EPSN/ASeres Therapeutics Revenue ResultsActual RevenueN/AExpected Revenue$6.35 millionBeat/MissN/AYoY Revenue GrowthN/ASeres Therapeutics Announcement DetailsQuarterQ3 2026Date11/4/2026TimeBefore Market OpensConference Call DateWednesday, November 4, 2026Conference Call Time8:30AM ETConference Call ResourcesEarnings HistoryCompany Profile Seres Therapeutics Earnings HeadlinesSeres Therapeutics (NASDAQ:MCRB) Stock Price Crosses Below Fifty Day Moving Average - Here's Why2 hours ago | americanbankingnews.comSeres Therapeutics (NASDAQ:MCRB) Share Price Crosses Below Fifty Day Moving Average - Time to Sell?September 30, 2026 | americanbankingnews.comAnthropic’s $40 million midterm moveAnthropic, creator of Claude, has committed $40 million to Public First Action, a nonpartisan group advocating AI safeguards, American leadership, and transparency ahead of the midterms. Alexander Green, Chief Investment Strategist of The Oxford Club, says the move signals Anthropic's shift from a technical story to a political and financial force, especially as IPO talk builds. A publicly accessible vehicle lists Anthropic as its largest holding, alongside Databricks and Anduril, and can be purchased through an ordinary brokerage account.October 8 at 1:00 AM | The Oxford Club (Ad)Seres Therapeutics, Inc.(NasdaqGS:MCRB) dropped from S&P Global BMI IndexSeptember 20, 2026 | marketscreener.comMSeres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 8, 2026 | globenewswire.comSeres Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment ConferenceSeptember 1, 2026 | globenewswire.comSee More Seres Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Seres Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Seres Therapeutics and other key companies, straight to your email. Email Address About Seres TherapeuticsSeres Therapeutics (NASDAQ:MCRB) is a biotechnology company focused on developing live biotherapeutics designed to restore and maintain the function of the human microbiome. Its research has centered on therapeutic products made from defined mixtures of microorganisms, rather than conventional broad-spectrum antibiotics or nonselective fecal material. The company’s leading product is VOWST, an orally administered microbiota-based therapy approved by the U.S. Food and Drug Administration for preventing the recurrence of Clostridioides difficile infection in adults following antibacterial treatment for recurrent infection. VOWST was developed to help reestablish a healthy intestinal microbiome and represented one of the first microbiome-based prescription products to receive FDA approval. Seres was founded in 2010 and is headquartered in Cambridge, Massachusetts. The company developed its products primarily for the U.S. market and worked with Nestlé Health Science on the commercialization of VOWST. Seres was led for much of its operating history by Eric Shaff, who served as president and chief executive officer. The company subsequently transferred its VOWST-related business to Nestlé Health Science and reduced its operations, reflecting a shift away from commercial activities toward a more limited corporate structure.View Seres Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Skydance Just Became a Media Giant—With an $80 Billion Debt LoadPenguin Solutions Is Soaring as AI Memory Demand ExplodesWall Street Is Betting These 3 Beaten-Down Stocks Have More Room to RunLamb Weston’s Turnaround Is Starting to Look RealRPM International’s Dividend King Status Just Got StrongerAI Chip Demand Gives Linde a New Growth CatalystAllient’s Data Center and Defense Momentum Is Raising the Stakes Upcoming Earnings Delta Air Lines (10/9/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
